Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Metformin

Antidiabetic agent
 
ALX-270-432-G005 5 g 36.00 USD
Do you need bulk/larger quantities?
 
Metformin is an antidiabetic agent. Reduces the cardiovascular complications of diabetes. Does not induce hypoglycemia. Inhibits hepatic gluconeogenesis via activation of the LKB1/AMPK pathway. Has antiproliferative effects in cancer cell lines.

Product Specification

Alternative Name:1,1-Dimethylbiguanide . hydrochloride
 
Formula:C4H11N5 . HCl
 
MW:165.6
 
CAS:1115-70-4
 
MI:14: 5938
 
RTECS:DU1800000
 
Purity:≥97% (Assay)
 
Appearance:White crystalline powder.
 
Solubility:Soluble in water (50mg/ml).
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Use/Stability:Stock solutions are stable for up to 6 months when stored at -20°C.
 
Handling:Hygroscopic.
 
270-432
Please mouse over
270-432

Product Literature References

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy: I.P. Yang, et al.; Ther. Adv. Med. Oncol. 11, 1758835919866964 (2019), Abstract; Full Text
Effect of human umbilical cord blood-derived mononuclear cells on diabetic nephropathy in rats: N.E. El-Ashmawy, et al.; Biomed. Pharmacother. 97, 1040 (2018), Abstract;
Metformin normalizes the structural changes in glycogen preceding prediabetes in mice overexpressing neuropeptide Y in noradrenergic neurons: L. Ailanen, et al.; Pharmacol. Res. Perspect. 6, e00389 (2018), Abstract; Full Text
H19 lncRNA alters methylation and expression of Hnf4a in the liver of metformin-exposed fetuses: J. Deng, et al.; Cell Death Dis. 8, e3175 (2017), Abstract; Full Text
Metformin alters DNA methylation genome-wide via the H19/SAHH axis: T. Zhong, et al.; Oncogene 36, 2345 (2017), Application(s): Cell culture, ARK2 and MCF-7 cells , Abstract;
Activation of the cAMP-PKA pathway antagonizes metformin suppression of hepatic glucose production: L. He, et al.; J. Biol. Chem. 291, 10562 (2016), Application(s): Cell culture, Abstract; Full Text
Compound C inhibits in vitro angiogenesis and ameliorates thrombin-induced endothelial barrier failure: D. Gündüz, et al.; Eur. J. Pharmacol. 768, 165 (2015), Application(s): Cell culture , Abstract;
Dehydroepiandrosterone activates AMP kinase and regulates GLUT4 and PGC-1α expression in C2C12 myotubes: T. Yokokawa, et al.; Biochem. Biophys. Res. Commun. 463, 42 (2015), Application(s): Cell Culture, Abstract;
Inhibition of integrin-linked kinase expression by emodin through crosstalk of AMPKα and ERK1/2 signaling and reciprocal interplay of Sp1 and c-Jun: Q. Tang, et al.; Cell Signal. 27, 1469 (2015), Application(s): Cell Culture, Abstract;
Long-Term Pancreatic Beta Cell Exposure to High Levels of Glucose but Not Palmitate Induces DNA Methylation within the Insulin Gene Promoter and Represses Transcriptional Activity: K. Ishikawa, et al.; PLoS One 10, e0115350 (2015), Application(s): Cell Culture, Abstract; Full Text
Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5: P.W. Caton, et al.; J. Endocrinol. 205, 97 (2010), Abstract;
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth: Y.H. Feng, et al.; J. Cell. Mol. Med. 15, 825 (2010), Abstract;
AMP-activated protein kinase in metabolic control and insulin signaling: M.C. Towler & D.G. Hardie; Circ. Res. 100, 328 (2007), Abstract;
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review: A. Natali and E. Ferrannini; Diabetologia 49, 434 (2006), Abstract;
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats: T. Misugi, et al.; Gynecol. Obstet. Invest. 61, 208 (2006), Abstract;
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells: M. Zakikhani, et al.; Cancer Res. 66, 10269 (2006), Abstract;
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin: R.J. Shaw, et al.; Science 310, 5754 (2005), Abstract;
Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin: C. Kilo, et al.; J. Diabetes Complications 17, 307 (2003), Abstract;
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group: Lancet 352, 854 (1998), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,